Gene activation is essential to the basic biological research and biomedicine. Therefore, various gene 16 activators such as activation domain-ZNF, TALE and CRISPR proteins have been developed for this end, in 17 which the CRISPR protein dead Cas9 (dCas9) is now most widely used. However, the current gene activators 18 are still limited by their inefficient gene activation activity. In this study, we developed a new strategy, 19 CRISPR-assistant trans enhancer, for activating gene expression in high efficiency by combining dCas9-20 VP64/sgRNA with a widely used strong enhancer, the CMV enhancer. In this strategy, a trans CMV enhancer 21 DNA was recruited to target gene by dCas9-VP64/sgRNA via annealing between 3′ end of sgRNA and CMV 22 enhancer. The trans enhancer activates gene transcription as the natural looped cis enhancer. The trans 23 enhancer could activate both exogenous reporter gene and variant endogenous genes in various cells, with 24 much higher activation efficiency than the current dCas9 activators. 25 Keywords: CRISPR/dCas9, CMV enhancer, trans enhancer, gene activation 26 27 28 2013; Perez-Pinera et al. 2013), VPR (VP64-p65-Rta) (Chavez et al. 2015), and KRAB (Zheng et al. 2018). 49 Additionally, the dCas9 protein was also fused with other functional domains with transcriptional regulatory 50 functions, such as p300(Hilton et al., 2015), LSD1(Kearns et al. 2015), Dnmt3a (Liu et al. 2016a; 51 Saunderson et al. 2017), and Tet1(Choudhury et al. 2016; Liu et al., 2016a). Based on these domains, 52 more elaborate activators have been developed for more potent activation of target genes in mammalian cells, 53 such as SunTag (dcas9-GCN4/sgRNA plus scFV-VP64) (Tanenbaum et al. 2014), and SPH (dCas9-54 GCN4/sgRNA plus scFV-p65-HSF1) (Zhou et al. 2018). More complex, some inducible dCas9 systems 55 have been developed to control activity of dCas9 activators in cells, such as light-activated CRISPR/Cas9 56 effector (Nihongaki et al. 2015; Polstein and Gersbach 2015), hybrid drug inducible CRISPR/Cas9 57 technology (HIT) (Lu et al. 2018), and CRISPR activator gated by human antibody-based chemically 58 induced dimerizers (AbCIDs) (Liu et al. 2018). A trouble of these typical dCas9 fusion proteins in their in 59
Introduction 29
Artificial activation of gene expression has important role in the basic biological research and biomedical 30 application. For example, gene function is often explored by artificially activating its expression in cells or 31 in vivo in basic research. In biomedicine, cells are often needed to be reprogrammed into induced stem (iPS) 32 cells or other differentiated cells by activating endogenous genes. In medicine, cancers can be treated by 33 inhibiting various kinases, activating genes enhancing immunity (Sagiv -Barfi et al. 2018) , apoptosis, and 34 differentiation (McClellan et al. 2015) . Therefore, various artificial gene activators have been developed. 35
For instance, the activation domain-fused zinc finger (ZNF), transcription activator-like effector (TALE), 36 and clustered regularly interspaced short palindromic repeats (CRISPR) associated proteins have been 37 developed for gene activation. In these proteins and complexes, the CRISPR-associated (Cas) proteins are 38 now most widely used due to its simplicity (Gao et al. 2014b) . 39 CRISPR is originally an immune system of bacteria to destroy the invaded microphage DNAs by 40 enzymatically digestion. The system has already been developed into a high efficient gene editing tool 41 recruitment sites, the modular scaffold RNAs that encode both target locus and regulatory action were 73 constructed (Zalatan et al. 2015) . For these recruitment RNA modules, the well-characterized viral RNA 74 sequences MS2, PP7, and com, which are recognized by the MCP, PCP, and Com RNA-binding proteins, 75 respectively, were used (Zalatan et al., 2015) . The transcriptional activation domain VP64 was fused to 76 each of the corresponding RNA-binding proteins (Zalatan et al., 2015) . By extending sgRNAs to include 77 modified riboswitches that recognize specific signals, a CRISPR-Cas9-based 'signal conductors' that 78 regulate transcription of endogenous genes in response to external or internal signals of interest (such as 79 drug) was created (Liu et al. 2016b) . Clearly, these chimeric sgRNAs limited by their long complexed RNA 80 aptamers and the cognate RNA-binding fusion proteins. 81
Although variant dCas9-based activators have been developed (Chen and Qi 2017), the current dCas9-82 based transcriptional activators are still inefficient at endogenous gene activation and reprogramming (Gao 83 et al. 2014a). By a systematic comparing of their relative potency and effectiveness across various cell types 84 and species (human, mouse, and fly) (Chavez et al. 2016) , it was found that the majority of second-85 generation activators showed improved levels of activation as compared to those of dCas9-VP64, in which 86 three activators including VPR, SAM, and Suntag were most potent. Across a range of target genes and 87 cellular environments, the VPR, SAM, and Suntag systems are consistently superior to the previous VP64 88 standard. Moreover, VPR, SAM, and Suntag generally fall within an order of magnitude of each other with 89 regard to fold increase in gene expression. More importantly, attempts to build an improved chimeric 90 activator by fusing elements from VPR, SAM, and Suntag were unsuccessful (Chavez et al., 2016) . 91 Therefore, future efforts to improve dCas9-based activators may benefit from exploring other unique 92 architectures or novel activation domains. 93
Almost three decades ago, the human cytomegalovirus (CMV) enhancer/promoter (referred to as CMV 94 enhancer hereafter) was found as a natural mammalian promoter with high transcriptional activity (Boshart 95 et al. 1985) . The late studies gradually found that the CMV enhancer is the known strongest promoter in production by gene engineering, and human gene therapy. We have recently further improved the 101 transcriptional activity of the CMV enhancer by changing the natural NF-κB binding sites in this enhancer 102 into artificially selected NF-κB binding sequences with high binding affinity . Therefore, 103
we conceived that an unique architecture may be constructed to further improve dCas9-based activators by 104 using the CMV enhancer. 105
In this study, mimicking the natural enhancer activating gene expression by a loop structure (Carter et CMV enhancer. The 3′ end of sgRNA was redesigned to add a short capture sequence in complementary 108 with a stick-end of a double-stranded CMV enhancer. The CMV enhancer is anchored to the promoter region 109 of target gene by dCas9/sgRNA. The dCas9/sgRNA-recruited CMV enhancer thus functions like a natural 110 looped cis enhancer in trans form. We found that the new activator could efficiently activate multiple genes 111 in 6 kinds of cells including 293T, HepG2, PANC-1, HeLa, A549, and HT29. Moreover, the new activator 112 activated expression of transcription factors HNF4α in HepG2 cells and E47 in PANC-1 cells could lead to 113 differentiation of these cancer cells. 114
Results

115
Conception of gene activation by a CRISPR-assistant trans enhancer 116
The principle of activating gene expression by a CRISPR-assistant trans enhancer is schematically illustrated 117 in Figure 1a . We modified sgRNA by adding a capture sequence to the 3′ end of normal sgRNA sequence, 118 which produces a 3′ end-extended sgRNA. Because the newly designed sgRNA will be used to capture a 119 trans enhancer DNA, we named it as capture sgRNA (csgRNA). Correspondingly, a linear double-stranded 120 CMV enhancer sequence with a free single-strand 3′ end was designed; we named the CMV fragment as 121 stick CMV (sCMV), which can interact with csgRNA by annealing to the 3′ capture sequence of csgRNA 122 via its stick end. In our conception, with these csgRNA and sCMV designing, when the csgRNA directs the 123 dCas9 protein to the target site that locates in the promoter region of interested gene, the sCMV will be 124 captured to the gDNA-bound dCas9/csgRNA. This interaction process will anchor a sCMV to the promoter 125 region of an interested gene. The anchored sCMV may thus activate the transcription of an interested gene 126 like natural looped cis enhancer. Because the dCas9/csgRNA-anchored sCMV functions like transcription 127 factors in trans, it can be regarded as trans enhancer, in contrast with natural enhancer that functions in cis. 
Effect of capture sequence on the function of sgRNA 138
An extended capture sequence was added to the sgRNA scaffold for annealing with the stick end of sCMV 139 enhancer fragment. To find whether the added capture sequence affects the function of sgRNA, we 140 synthesized a normal sgRNA and three csgRNAs targeting to a same site of HNF4α promoter by in vitro 141 transcription. Three csgRNAs had different capture sequences. We used these sgRNAs to associate with the 142 Cas9 endonuclease to cut a 732-bp HNF4α promoter fragment. The results indicate that the target DNA 143 could be digested by all sgRNAs, including three csgRNAs with variant capture sequences (Figure 1b) . This 144 indicates that the capture sequence exerts no effect on the sgRNA function. 145
Activation of an exogenous reporter gene by trans enhancer 146
To find whether the CRISPR-assistant trans enhancer is able to activate gene expression, we constructed a 147 reporter construct of HNF4α promoter, pEZX-HP-ZsGreen. We then transfected the 293T cells with sCMV, 148 dCas9, and csgRNA2. We found that the system activated the expression of reporter gene ZsGreen ( Figure  149 2; dCas9/csgRNA2-sCMV). The activation level is similar to that of dCas9-VP64/sgRNA. Because we used 150 a dCas9 that has no fused transcriptional activation domain like VP64 in the trial transfection, this indicates 151 that the sCMV can not only interact with the dCas9/csgRNA in cell as we conceived, but also function as a 152 transcription factor to activate gene expression as we expected. However, the activation level of 153 dCas9/csgRNA & sCMV system is far below the activation strength of cis CMV enhancer. 154
To improve the transcriptional activation performance of dCas9/csgRNA & sCMV system, we then 155 transfected the 293T cells with a dCas9-VP64/csgRNA2 & sCMV system. As a result, we found that the 156 system greatly activated the expression of reporter gene (Figure 2 ; dCas9-VP64/csgRNA2-sCMV). As a 157 control, the transfection with dCas9-VP64/csgRNA2 & blunt CMV (bCMV) system obtained an activation 158 level similar to that of dCas9-VP64/sgRNA (Figure 2) , indicating that the sCMV genuinely contributed to 159 the gene expression activation. More importantly, we found that the VP64 fused to the dCas9 protein could 160 significantly improve the function of sCMV, possibly by addition or synergy. We then transfected the 293T 161 cells with other two csgRNAs, csgRNA1 and csgRNA3, together with dCas9-VP64 & sCMV. We found that 162 these two csgRNAs also obtained high level activation (Figure 2) , despite inferior to csgRNA2. The 163 transcriptional activation function of trans sCMV was also confirmed by another control transfection, 164 dCas9/csgRNA2 & bCMV, which showed no transcriptional activation (Figure 2) . 165
To confirm the function of trans enhancer, we also performed more negative control transfections in 293T 166 cells, including the sole dCas9-VP64, sgRNA, and pEZX-HP-ZsGreen, and dCas9-VP64 plus pEZX-HP-167
ZsGreen. These transfections all didn't activate the reporter gene expression ( Supplementary Figure 1) . 168
These data verify that the trans enhancer sCMV can play transcriptional activation role by combination with 169 dCas9/csgRNA. Moreover, the typical transcription activation domain VP64 fused to dCas9 can further 170 improve the transcriptional activation performance of trans enhancer sCMV. Therefore, we adopted the 171 dCas9-VP64/csgRNA2 & sCMV system to perform subsequent more characterizations of CRISPR-assistant 172 trans enhancer. 173 
Comparison of trans CMV enhancer with VPR 216
The VPR transcription-activating domain has been shown with higher transcriptional activation ability than 217 VP64. Therefore, we next compared the trans enhancer with this strong transcription activation domain. We 218 transfected the 293T and HepG2 cells with dCas9-VP64/csgRNA, dCas9-VPR/csgRNA, and dCas9-219 VP64/csgRNA & sCMV, in combination with ZsGreen reporter construct, respectively. The results reveal 220 that dCas9-VPR/csgRNA had better transcriptional activation efficiency than dCas9-VP64/csgRNA as 221 reported by many previous studies (Figure 4b) . However, the dCas9-VP64/csgRNA & sCMV showed far 222 higher transcriptional activation efficiency than dCas9-VPR/csgRNA (Figure 4b) . Moreover, we found that 223 the former activated the ZsGreen expression in more cells than the latter at any fluorescence intensity 224 threshold. This means that the trans enhancer sCMV not only make more cells produce fluorescence, but 225 also make more cells produce higher fluorescence than dCas9-VPR/sgRNA. These data further demonstrate 226 the great transcriptional activation ability of CRISPR-assistant trans enhancer. 227
Activation of endogenous genes by trans enhancer
To investigate the transcriptional activation of endogenous genes by trans enhancer, we chose 10 genes as 229 activating targets, including HNF4α, E47 (TCF3), ASCL1, Ngn2, Oct4, Nanog, TNFAIP3, CASP9, CSF3, 230
and Sox2. We designed one promoter-targeting sgRNA for each of these genes. We then transfected 7 231 different cell lines with the dCas9-VP64/csgRNA2 & sCMV. At the same time, all cells were simultaneously 232 transfected with dCas9-VP64/sgRNA and dCas9/csgRNA & sCMV as controls. After the gene transcription 233 was detected by qPCR, the expression fold of target genes in the cells transfected by dCas9/csgRNA2 & 234 sCMV relative to those only transfected by Lipofectamine 2000 was calculated. By comparing the 235 transcriptional activation effects of these 10 genes in different cell lines, we found that the dCas9-236 VP64/csgRNA2 & sCMV always activated the highest transcription of all genes in all cells (Figure 5) . As 237 in exogenous gene activation, the dCas9/csgRNA & sCMV could better activate target genes than dCas9-238 VP64/sgRNA in all cells. Interestingly, we found that the expression of 6 genes including HNF4α, TCF3, 239 ASCL1, Ngn2, TNFAIP3, and CSF3 were always highly activated by three systems in all cells. However, the 240 expression of other 4 genes including Oct4, Sox2, Nanog, and CASP9, was just less activated. These results 241 demonstrate that the CRISPR-assistant trans enhancer can activate the expressions of variant endogenous 242 genes in various cells. These results also indicate that the trans sCMV has a synergistic effect with the dCas9-243 fused transactivation domain VP64 in activating gene transcription. 244 
Activation of tumor cell differentiation genes by trans enhancer 256
Finally, we explored whether the trans enhancer can be used to activate critical genes related to tumor 257 differentiation therapy. We selected two transcription factors that were reported to induce tumor cell 258 differentiation, HNF4α and E47. The former has been reported to induce the differentiation of cancer cell 259
HepG2, and the latter has been reported to induce the differentiation of cancer cell PANC-1. 260
We firstly transfected the HepG2 and PANC-1 cells with the dCas9/csgRNA & sCMV system that targets 261 to a single site in the promoter region of HNF4α and E47 genes, respectively. The qPCR detection of gene 262 expression indicates that the two genes were highly activated in the transfected cancer cells (Figure 5 ; see 263
HepG2 and PANC-1 cells). Moreover, with the activation of HNF4α in HepG2 cells, the expression of 264 CD133 and CD90 was down-regulated (Figure 6a) . In contrast, the expression of p21 was highly up-265 regulated. The expression of some typical genes that are involved in the establishment or maintenance of 266 pluripotency, including Oct3/4, Sox2, Nanog, c-Myc, LIN28, and Klf4, was also down-regulated (Figure 6a) . 267
On the contrary, the expression of multiple genes related to healthy liver function, including GS, BR, ALDOB, 268
CYP1a2, PEPCK, APOCIII, G-6-P, and HPD, was highly up-regulated (Figure 6b) . 269
Similarly, when the E47 gene was activated in the PANC-1 cell, the expression of CD133 and CD90 was 270 down-regulated (Figure 6c) . In contrast, the expression of p21 and TP53INP1 was highly up-regulated. The 271 expression of some typical genes that are involved in the establishment or maintenance of pluripotency, 272
including Oct3/4, Sox2, Nanog, c-Myc, LIN28, and Klf4, was down-regulated (Figure 6c) , while the 273 expression of several genes related to healthy pancreas function, including MIST1, PRSS2, CELA3A, and 274 CPA2, was significantly up-regulated (Figure 6d) . The p21 and TP53INP1 was required by E47-induced 275 cell cycle arrest (Figure 6d) . The MIST1 normally regulated the acinar maturation pathways. The gene 276 PRSS2, CELA3A, and CPA2 code the digestive enzyme trypsin, elastase 3, and carboxypeptidase A2, 277
respectively. 278
Besides detecting gene expression, we also detected the physiological phenotypes of transfected cells, 279
including proliferation, migration, and invasion. We characterized the cell proliferation by detecting cell 280 cycles. The results indicate that the HNF4α and E47 activation by trans enhancer induced significant cell 281 growth arrest (increased G 0 /G 1 cells) in HepG2 and PANC-1 cells, respectively (Figure 7a) . The wound-282 healing assay reveals that the migration ability of two cell lines was significantly decreased by the 283 transfection of trans enhancer (Figure 7b, Supplementary Figure 7) . The transwell assay also revealed that 284 the trans enhancer transfection resulted in significant decrease of invasion ability of two cell lines 285 (Supplementary Figure 8) . These physiological changes of the transfected cells are in agreement with the 286 gene expression changes detected above. 287 
Activation of endogenous gene by trans enhancer consisting of VPR and CMV 305
Finally, we expected to known whether the combination of dCas9-VPR/csgRNA and sCMV could obtain 306 higher transcriptional activation than the combination of dCas9-VP64/csgRNA and sCMV. We thus 307 transfected 293T cell with dCas9-VP64 and dCas9-VPR together with csgRNA2 and sCMV to activate the 308 (Liu et al., 2018) . The mouse embryonic fibroblasts can be converted to induced neuronal cells by activating endogenous Brn2, Ascl1, and Myt1l genes with VP64 dCas9 VP64 (Black et al. 2016) . 317
The in vivo target genes can be activated by MPH to ameliorate disease phenotypes in mouse models of type 318 I diabetes, acute kidney injury, and muscular dystrophy (Liao et al., 2017) . The brain astrocytes can be 319 directly and efficiently converted into functional neurons in vivo by activating Ascl1, Neurog2 and Neurod1 320 genes with SPH (Zhou et al., 2018) . These studies makes CRISPR therapies the grade not the cut (Burgess 321 2018). However, dCas9-based transcriptional activators are still inefficient at endogenous gene activation 322 and reprogramming (Gao et al., 2014a) . 323
In this study, we developed a new dCas9-based gene activation system by recruiting a CMV enhancer in 324 trans to target gene via dCas9 associated with a simple chimeric sgRNA. This study revealed that the trans 325 enhancer consisted of dCas9-VP64/csgRNA and sCMV could highly activate the expression of variant 326 exogenous and endogenous genes in various mammalian cells, more efficiently than the currently widely 327 used dCas9-VP64 and dCas9-VPR. This study thus developed a new strategy to activating endogenous genes, 328 trans enhancer. To our knowledge, this is the first report to activate gene expression with an enhancer DNA 329 in trans form. This creative strategy has its advantages over the current dCas9-based gene activation systems. (Zalatan et al., 2015) . Our csgRNA only harbors a 24-bp 344 short sequence at the end of normal sgRNA. It should be noted that we originally designed three different 345 csgRNAs that have different capture sequences. We found that all of them work in the trans enhancer system; 346 however, one (csgRNA2) showed the optimal performance. It should be pointed out that the capture 347 sequences were artificially designed so that they have no complementary sequences in human cells, which 348 is important for their high-efficiency specific annealing with sCMV. This study also reveals that the sCMV 349 can anneal with csgRNA in the nuclear of human cells. This interaction successfully recruits the trans 350 enhancer DNA to the target genes by dCas9/csgRNA. Clearly this interaction is more simple than that 351 between RNA aptamers and RNA-binding proteins used in the current sCas9 activation systems. This 352 develops a new approach for biomolecule recruitment in cells, which may be useful for future application. should be conceived to address the problem for the in vivo application of trans enhancer. For example, fusing 362 a DNA-binding domain to dCas9 that can bind trans enhancer with its binding sites. 363
In this study, we selected 10 endogenous genes to be activated by trans enhancer, including HNF4α, E47, 364 Ascl1, Ngn2, Oct4, Sox2, Nanog, TNFAIP3(A20), CASP9, and CSF3. These genes are not randomly selected. 365
Most of these genes are transcription factors, including HNF4α, E47, Ascl1, Ngn2, Sox2, Oct4, and Nanog. 366
The combination of Ascl1, Ngn2, and Sox2 has been reported to be used to directly reprogram fibroblasts 367 into nerve cells (Zhao et al. 2015) . The combination of Oct4, Sox2, and Nanog has been widely used to Caspase9 is a key gene making cell apoptosis (Li et al. 2017) . CSF3 codes granulocyte-colony stimulating 373 factor (G-CSF), a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and 374 release them into bloodstream (Cetean et al. 2015) , which is widely used in chemotherapy to enhancer the 375 immunity of cancer patients. This study revealed that the genes including HNF4α, E47, Ascl1, Ngn2, 376 TNFAIP3(A20), and CSF3 were highly activated by trans enhancer in all transfected cells. However, the 377 pluripotency-related genes, including Oct4, Sox2 and Nanog, and CASP9 were not highly activated as others, 378
which may be related to the tight control of these critical genes. 379
Materials and methods
380
Vector construction 381
To apply the CRISPR/dCas9 expression system to transfection in cells, plasmid containing sgRNA derived 382 by U6 promoter was constructed. We cloned a lac operon sequence with BbsI and BsaI sites at both ends 383 from empty pEASY-Blunt-simple (Transgen, CB101-01) using Pfu High fidelity polymerase (Transgen, 384 AS221-01) with primers Lac-px-F and Lac-px-R (Supplementary Table 1) . This lac operon sequence was 385 ligated into px458 (Addgene plasmid ID: 42230) to construct px458-lac. The ligation product was 386 transformed into DH5a and then screened the blue colonies. The px458-lac was verified by sequencing. Then 387 we designed three flanking sequences. The flanking sequence was add to 3′-end of gRNA scaffold sequence 388 by PCR amplification using a forward primer (U6-F) and one of three reverse primers containing different 389 flanking sequences, U6-1-R, U6-2-R, and U6-3-R (Supplementary Table 1) , in which the gRNA scaffold 390 sequence cloned in the px458-lac was used as template. The products were cloned into the pEASY-Blunt-391 simple, which produced the csgRNA expression vector named as pEASY-csgRNA. The csgRNA refers to 392 capture sgRNA that has a 3′ extended flanking sequence. All flanking sequences were 24-bp in length. 393
Ten vital genes, including HNF4α, TCF3(E47), ASCL1, Ngn2, Oct4, Nanog, TNFAIP3, CASP9, CSF3, 394
and Sox2, were chosen as target. The sgRNA target sites specific to each gene was designed by CHOPCHOP 395 (https://chopchop.rc.fas.harvard.edu/) . The pEASY-csgRNA expressing a particular csgRNA was 396 constructed with a procedure described by Supplementary Figure 10 . The chemically synthesized 397 complementary oligonucleotides (Supplementary Table 2) with a 20-bp target-specific region flanked by 398 two BbsI sites were diluted to 10 µM and mixed at the same molar. The final concentration of each 399 oligonucleotide in a reaction was 1 μM. After mixing well, the complementary oligonucleotides were 400 denatured with high temperature (95℃) and annealed through a natural cooling process. The hybridization 401 product were diluted 800 times and then ligated into pEASY-csgRNA. The ligation reaction (10 μL) 402 consisted of 1 µL BbsI, 0.3 μL T4 DNA ligase, 1 μL 10× T4 DNA ligase buffer, 10× Bovine Serum Albumen 403 (final concentration of 0.1 mg/mL), 50 ng plasmid pEASY-csgRNA, and ddH 2 O up to 10 µl total reaction 404 volume. The ligation reactions was run cycle as fellow: 10 rounds of 37℃ 5 min and 16℃ 10 min, 37℃ 405 30 min, and 80℃ 5 min. The ligation product was introduced into DH5α competent cells and white clones 406 were screened by blue-white screening on LB agar plates with 100 µg/mL Ampicillin, 40 µL of 20 mg/mL 407 X-gal and 40 µL of 0.1 M IPTG. The vectors were validated by sequencing. Then the linear sgRNA or 408 csgRNA expression sequences were amplified from the plasmid pEASY-csgRNAs by PCR using a forward 409 primer U6-F and one of reverse primer U6-R, U6-1-R, U6-2-R, and U6-3-R. The primer U6-F and U6-R 410 were used to amplify the normal sgRNA expression template (named as U6-sgRNA), and the primer U6-F 411 and U6-1/2/3-R were used to amplify the csgRNA expression template (named as U6-csgRNA). The PCR 412 products were purified by PCR clean kit (Axygen). These sequences were used to transfect cells as sgRNA 413 transcription templates. 414
The complete sequence of CMV enhancer/promoter was amplified from pEGFP-N1 by using a forward 415 primer (CMV-F; Supplementary Table 1 ) and one of reverse primers that had a special flanking sequence 416 (CMV-1-R, CMV-2-R, or CMV-3-R; Supplementary Table 1 ). The amplified CMV promoter fragment 417 harbors an Nt.BbvCI site at its one end. Then the amplified CMV promoter fragment was digested by 418
Nt.BbvCI. The digested CMV promoter fragment was mixed with a complementary oligonucleotide (CS-1-419 R, CS-2-R, or CS-3-R; Supplementary Table 1 ) and then denatured at 85°C for 10 min. The denatured 420 mixture was then naturally cooled to room temperature. The complementary oligonucleotide has the same 421 sequence with the final 3′ single-strand stick end of CMV promoter fragment. The complementary 422 oligonucleotide was used to remove the denatured oligo from CMV promoter fragment. The CMV promoter 423 fragment was purified with PCR clean kit and used as linear stick-end CMV (sCMV) promoter fragment. 424
The untreated CMV promoter fragment was used as a blunt-end CMV (bCMV) control. 425 A ZsGreen reporter construct was constructed by cloning an HNF4α promoter sequence into the upstream 426 of ZsGreen gene. A 1000-bp HNF4α promoter sequence was amplified from the genomic DNA of HepG2 427 cells by PCR using primers HNF4α-P-F and HNF4α-P-R (Supplementary Table 1) . Then the promoter 428 sequence was ligated into the pEZX-ZsGreen, which produced an HNF4α promoter reporter construct named 429 as pEZX-HP-ZsGreen. The vector pcDNA-dCas9-VP64 was purchased from Addgene (plasmid ID: 47107). 430
The VP64 sequence in the pcDNA-dCas9-VP64 was deleted to construct pcDNA-dCas9. The VP64-p65-431 Rta (VPR) transcription-activating domain sequence was ligated into pcDNA-dCas9 to construct pcDNA-432 dCas9-VPR. 433
DNA cutting with Cas9/csgRNA 434
A sgRNA targeting to the HNF4α promoter sequence was selected. The sgRNAs were prepared by an in 435 vitro transcription using T7 RNA polymerase (M0251S, NEB). The sgRNA transcription template was 436 prepared by PCR amplification of sgRNA-coding sequence cloned in the sgRNA expression plasmid 437 (pEASY-csgRNA) with a forward primer, HNF4α-T7-F (Supplementary Table 1) , which containing a T7 438 promoter sequence (TAATACGACTCACTATAG, transcription beginning with the 3' G), and one of four 439 reverse primers, U6-R, U6-1-R, U6-2-R, and U6-3-R (Supplementary Table 1) . A normal sgRNA (HNF4α-440 sgRNA) and three csgRNAs (HNF4α-csgRNAs) were prepared. A 732-bp HNF4α promoter fragments was 441 amplified from pEZX-HP-ZsGreen-A by PCR using primers HNF4α-sP-F and HNF4α-sP-R 442
( Supplementary Table 1 ). The Cas9 digestion reaction (30 μL) consisted of 1×Cas9 Nuclease Reaction 443
Buffer, 1 µM Cas9 Nuclease (NEB, M0386T), and 300 nM HNF4α-sgRNA or HNF4α-csgRNA. The Cas9 444 nuclease reaction was firstly incubated at 25 °C for 10 min. The Cas9 reaction was then added with 400 ng 445 of purified 732-bp HNF4α promoter fragment and incubated at 37 °C for 15 min. Finally, Cas9 nuclease was 446 inactivated at 65 °C for 10 min. The reaction was run with 1.5% agarose gel electrophoresis.
Cell culture and transfection 448
293T, HepG2, A549, SKOV3, HT29, PANC-1, and HeLa were obtained from the cell resource center of 449
Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and maintained in an incubator 450 set at 37 °C and 5% CO 2 . Cells were cultured in the Dulbecco's Modified Eagle Medium (DMEM) or 451
Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% FBS, 100 units/mL 452 penicillin, and 100 µg/mL streptomycin. Cells at >70% confluency in each well of 12-well plate were 453 transfected with 800 ng total DNA, including 500 ng plasmid (pcDNA-dCas9, pcDNA-dCas9-VP64, or incubated for 20 min at room temperature before being added to each well. After incubated cell with 462 transfection solution for 4 h, the medium of each well was replaced with 800 μL of fresh DMEM or RPMI 463 Supplementary Table 2 . Oligonucleotide used to prepare target-specific regions (20 bp) of sgRNA Gene Name Sequence
HNF4α
HNF4α-sg-S 5′-AGGAAGACGGCACCGGCCAGTCACTTAGGGAACCCGGTTTGGGTCTTCGA-3′
Sox2-sg-AS 5′-TCGAAGACCCAAACCCTCGCCTGCCCCCTCCTCCCCGGTGCCGTCTTCCT-3′ S, sense; AS, antisense.
Gene Name Sequence
Hnf4a
Hnf4a-F 5′-GACATTCGGGCGAAGAAGAT-3′
Supplementary Figures
Supplementary Figure 1 TGAGATCCAAAACTGAGACAAAAGAAACGGGGCTGTTCCAAAAAAAAAGCTAGGTGGCAGG  TGTCTAACATGCCAGGGAGCTAAAACAGAGTGTGTGAGTTTCAGCAGCAGGTTGAATTTAGA  ATGGGGAAGGAGACCAGAGGAGACGCCAGACAGGATGACTTTGTCCCATTGGCCTGGAGG  CAGCCCCATGTTTCTCCACCCCTCATATCACTCACCAGTTTGTAATAGTATCTTTGAATGACGA  TCTGATTAAGGTCCGTCTCCTCCATTAGTCCACAAGTTTCGGGGGTACATCTACTTTGCTCAT  TTCCATATCCCCAGAGTCTAGCACAAGGCCTGGTACATAGTAGGTGCTCAATAAATATGTTAGA  TGAAAGGAAGATAACACCTCTATGTACTAGCAGTGAGACTCCAGGCATGCAATTTCTCTCTGT  CCTTCAGTCCCTTCATCTCAAGGTTTAATTTAAATATGGTAACGCCTGTATGCAACTCCCAGCA  TCCAGTAGGCACTCACTAAACACAGTTCTCCACCCTCCTTTTTTCCTCTGCCCCTCCCTCGG  TTTTCCCACTACTTCCTGCATGGTGACACACCCATAGTTTGGAGCCATAAAACCCAACCCAG  GTTGGACTCTCACCTCTCCAGCCCCTTCTGCTCCGGCCCTGTCCTCAAATTGGGGGGCTGA  TGTCCCCATACACCTGGCTCTGGGTTCCCCTAACCCCAGAGTGCAGGACTAGGACCCGAGT  GGACCTCAGGTCTGGCCAGGTCGCCATTGCCATGGAGACAGCAACAGTCCCCAGCCGCGG  GTTCCCTAAGTGACTGGTTACTCTTTAACGTATCCACCCACCTTGGGTGATTAGAAGAATCAAT  AAGATAACCGGGCGGTGGCAGCTGGCCGCACTCACCGCCTTCCTGGTGGACGGGCTCCTG  GTGGCTGTGCTGCTGCTGTGAGCGGGCCCCTGCTCCTCCATGCCCCCAGCTCTCCGGCTG  GGTGGGCTTAAGCTTCTCGACTTCCAGCTTGGCATAGAGGGTATATAATGGAAGCTCGACTT  CCAGATCCGGTACTGTTGGTAAAGCCACCGGATCCAGCCACCATGGCCCAGTCCAAGCACG  GCCTGACCAAGGAGATGACCATGAAGTACCGCATGGAGGGCTGCGTGGACGGCCACAAGT  TCGTGATCACCGGCGAGGGCATCGGCTACCCCTTCAAGGGCAAGCAGGCCATCAACCTGTG  CGTGGTGGAGGGCGGCCCCTTGCCCTTCGCCGAGGACATCTTGTCCGCCGCCTTCATGTA 
